Drug intelligence / Profile preview

tirnovetmab

Development stage: Preclinical
Lead developer: Elanco
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Tirnovetmab is a monoclonal antibody developed by Kindred Biosciences for the treatment of canine atopic dermatitis. It was identified as a potential blockbuster drug in the pet dermatology market. Following the acquisition of Kindred Biosciences by Elanco Animal Health, tirnovetmab became part of Elanco's pipeline, aimed at expanding their presence in the pet health and dermatology sectors.

Brand names: Befrena
Other names: tirnovetmab

Targets

IL31 (IL-31)

Beyond the preview

Go deeper on tirnovetmab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tirnovetmab.

Explore the full profile